bluuebunny/crossref_metadata_2025_split huggingface dataset:
Will the real invasive snail please stand up? A phylogenetic reconsideration of Paralaoma servilis (Shuttleworth, 1852) (Gastropoda: Stylommatophora: Punctidae)
Authors: Nekola Jeffrey C , Brook Fred J , Foon Junn Kitt , Horsáková Veronika , Ishii Yasuto , Köhler Frank , Líznarová Eva , Nováková Markéta , Saito Takumi , Salvador Rodrigo B , Horsák Michal 
Published: January 2025

Abstract
We reconsider the biodiversity and biogeography of Paralaoma servilis—believed to be one of the most globally invasive exotic land snails—through integrative empirical revision. Phylogenies obtained from nDNA (ELAV, ddRAD genomics) and mtDNA (COI) demonstrate that the current classification is in error, with there being at least five distinct species within P. servilis s.l. The P. servilis group as interpreted here thus includes: P. servilis, inferred to be native to south-western Pacific Rim with an adventive distribution minimally spanning North America, Europe, and the Macaronesian islands of the eastern Atlantic Ocean; P. amblygona (Reinhardt, 1877), native to Honshu, Japan; P. borealis (Pilsbry and Y. Hirase, 1905), native to Hokkaido, Japan along the Pacific Rim to the SW North American mountains; P. caputspinulae (Reeve, 1852), native to New Zealand and Lord Howe Island; and P. morti (J.C. Cox, 1864), native to south-eastern Australia. Within P. servilis, invasiveness appears limited to a single clade that may have arisen along the California coast. The work presented here is a reminder that taxonomic concepts that have not been subjected to empirical vetting can generate poor biodiversity perspectives and non-optimal conservation strategies when native species are treated as exotics.
Genome-Wide Analysis of Moniliophthora roreri Facilitates the Development of Species-Specific Primers for Biomonitoring Frosty Pod Rot of Cacao
Authors: Reis Sara Pereira Menezes , Diorato Vanessa Santana , dos Santos Júnior Almiro Neves , Barbosa Ceslaine Santos , Ciampi-Guillardi Maisa , de Andrade Edson Mario , Solis Karina Zoila , Manco Maria Julia Silva , França Franciely Santos , Vera Danilo , Catota Arturo Ivan Garzón , Niella Givaldo Rocha , Arévalo-Gardini Enrique , Bonilla José Luis Solís , Micheli Fabienne , Wong Julio Alfonso Chia , Gramacho Karina Peres 
Published: January 2025

Detecting pathogens in asymptomatic plants allows for a rapid response to emerging threats, such as the introduction of new pathogens or the emergence of new resistant strains. Frosty pod rot ( Moniliophthora roreri) significantly jeopardizes cacao production by impairing pod quality and yield. However, early diagnosis is challenging due to its prolonged incubation period, compounded by symptoms resembling those of M. perniciosa, the causative agent of witches’ broom disease. To address this, a specific and sensitive quantitative real-time PCR (qPCR) assay was developed for M. roreri detection. This involved testing diagnostic primers against a panel of 252 DNA samples collected from target and nontarget species of over 13 fungal species commonly found in cacao plantations from various regions. Species-specific primer pairs were obtained through genomic comparison of Moniliophthora spp. genomes. Two primer sets, Mr77F/R and Mr78F/R, were validated using a set of M. roreri DNA samples representative of different genetic groups (Ecuador, Peru, and Mexico) and M. perniciosa, from which no amplification was detected. The limit of detection (LOD) was determined to be 0.9 ng/µl for both primers Mr77F/R and Mr78F/R. Using this set of primers, the amplification of M. roreri DNA from naturally diseased cocoa pods at various stages of infection was also successful. At the practical level, the data provided here confirm the value of molecular diagnostic testing for the early detection of M. roreri. These features are desirable for improving fungal diagnostic capacity and assisting in devising strategies to avoid pathogen dispersion within cacao-growing regions. [Formula: see text] Copyright © 2025 The Author(s). This is an open access article distributed under the CC BY-NC-ND 4.0 International license .
Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms
Authors: Menegaz de Almeida Artur , Oliveira Paloma , Lopes Lucca , Leite Marianna , Morbach Victória , Alves Kelly Francinny , Barros Ítalo , Aquino de Moraes Francisco Cezar , Prevedello Alexandra 
Published: January 2025

OBJECTIVE:
To assess the efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in menopausal women.

DATA SOURCES:
MEDLINE, EMBASE, and Cochrane databases were systematically searched until August 22, 2024. Because the Cochrane Library included all the identified randomized controlled trials (RCTs), it was unnecessary to search ClinicalTrials.gov. The following words made up the search strategy, which was applied to the three databases: fezolinetant, elinzanetant, vasomotor symptoms, and menopause.

METHODS OF STUDY SELECTION:
Only RCTs comparing fezolinetant and elinzanetant with placebo for vasomotor symptoms in menopausal women were included.

TABULATION, INTEGRATION, AND RESULTS:
We extracted the number of patients, mean age, body mass index (BMI), and number of patients who underwent oophorectomy. Data were examined with the Mantel–Haenszel method and 95% CIs. Heterogeneity was assessed with I
2 statistics. R 4.3.2 was used for statistical analysis. Seven RCTs with 4,087 patients were included in the analysis. Fezolinetant and elinzanetant were associated with diminished vasomotor symptom frequency: fezolinetant 30 mg (mean difference 2.16, 95% CI, 1.54–2.79, I
2=0%), fezolinetant 45 mg (mean difference 2.54, 95% CI, 1.86–3.21, I
2=0%), and elinzanetant 120 mg (mean difference 2.99, 95% CI, 1.74–4.23, I
2=0%). Both drugs also showed a decrease in vasomotor symptom severity: fezolinetant 30 mg (mean difference 0.20, 95% CI, 0.09–0.33, I
2=0%), fezolinetant 45 mg (mean difference 0.24, 95% CI, 0.13–0.34, I
2=0%), and elinzanetant 120 mg (mean difference 0.36, 95% CI, 0.26–0.46, I
2=0%). Elinzanetant 120 mg showed a significant improvement in sleep quality (mean difference 4.65, 95% CI, 3.73–5.56, I
2=0%). Elinzanetant 120 mg was associated with the occurrence of drug-related adverse events (11.70% vs 20.75%, risk ratio [RR] 0.57, 95% CI, 0.39–0.82, I
2=19%) and headache (2.54% vs 8.0%, RR 0.32, 95% CI, 0.16–0.64, I
2=0%).

CONCLUSION:
In this meta-analysis, consistent results suggest that fezolinetant and elinzanetant are associated with beneficial outcomes in menopausal women with vasomotor symptoms. Elinzanetant provided a larger effect size in vasomotor symptom frequency and severity reduction and greatly improved sleep quality compared with fezolinetant.

SYSTEMATIC REVIEW REGISTRATION:
PROSPERO, CRD42023469952.
Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial
Authors: Simões Eric A. F. , Pahud Barbara A. , Madhi Shabir A. , Kampmann Beate , Shittu Emma , Radley David , Llapur Conrado , Baker Jeffrey , Pérez Marc Gonzalo , Barnabas Shaun L. , Fausett Merlin , Adam Tyler , Perreras Nicole , Van Houten Marlies A. , Kantele Anu , Huang Li-Min , Bont Louis J. , Otsuki Takeo , Vargas Sergio L. , Gullam Joanna , Tapiero Bruce , Stein Renato T. , Polack Fernando P. , Zar Heather J. , Staerke Nina B. , Padilla María Duron , Richmond Peter C. , Sarwar Uzma N. , Baber James , Koury Kenneth , Lino Maria Maddalena , Kalinina Elena V. , Li Weiqiang , Cooper David , Anderson Annaliesa S. , Swanson Kena A. , Gurtman Alejandra , Munjal Iona 
Published: January 2025

OBJECTIVE:
To evaluate descriptive efficacy data, exploratory immunogenicity data, and safety follow-up through study completion from the global, phase 3 MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal vaccination trial of bivalent respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVpreF).

METHODS:
MATISSE was a phase 3, randomized, double-blinded, placebo-controlled trial. Healthy pregnant participants aged 49 years or younger at 24–36 weeks of gestation were randomized (1:1) to receive a single RSVpreF 120 micrograms or placebo dose. Primary efficacy endpoints included newborn and infant severe RSV-associated medically attended lower respiratory tract illness within 180 days after birth. The RSV-A and RSV-B serum neutralizing antibody titers were determined in a subset of pregnant participants and their newborns.

RESULTS:
In this final analysis, 7,420 pregnant participants were randomized, and 7,307 children were born (RSVpreF n=3,660, placebo n=3,647). Vaccine efficacy, defined as protection against newborn and infant severe RSV-associated medically attended lower respiratory tract illness, was 82.4% (95% CI, 57.5–93.9) and 70.0% (95% CI, 50.6–82.5) within 90 and 180 days of birth, respectively. The RSVpreF induced robust immune responses in pregnant participants and resulted in highly efficient transfer of maternal antibodies to their newborns across subgroups (by gestational age at delivery and at vaccination, number of days from vaccination to delivery, country, maternal age). Final RSVpreF safety results in pregnant and newborn and infant participants were consistent with the primary analysis with no new safety concerns identified.

CONCLUSION:
This final analysis of MATISSE trial data confirms the primary analysis conclusions: Maternal vaccination with RSVpreF has a favorable safety profile in both pregnant and newborn and infant participants and demonstrates efficacy against RSV-associated lower respiratory tract illness in infants through age 6 months. The RSVpreF induces robust immune responses in pregnant individuals, with corresponding high RSV-neutralizing titers in their newborns.

CLINICAL TRIAL REGISTRATION:

ClinicalTrials.gov, NCT04424316.
Slow-Coagulation Transscleral Cyclophotocoagulation in Pseudoexfoliation Glaucoma
Authors: Khodeiry Mohamed M. , Yusuf Ramsey , Dorizas Christopher A. , Elhusseiny Abdelrahman M. , Sayed Mohamed S. , Ruan Merry , Lee Richard K. 
Published: January 2025

Purpose:
To evaluate the outcomes of slow-coagulation transscleral cyclophotocoagulation (SC-TSCPC) in pseudoexfoliation glaucoma (PXG).

Methods:
A single-center, retrospective non-comparative study including consecutive patients with medically uncontrolled PXG who underwent SC-TSCPC (1250-milliwatt power and 4-second duration). The primary outcome measure was surgical success (defined as intraocular pressure (IOP) between 6 - 21 mmHg with ≥20% reduction compared to baseline and no need for further glaucoma surgeries or development of vision-threatening complications). Success was considered qualified when achieved with additional glaucoma medications and complete when achieved without additional glaucoma medications. The secondary outcomes included IOP, glaucoma medication numbers, visual acuity, and postoperative complications at 1 and 2 years after laser treatment.

Results:
This study included 48 eyes of 48 patients. The median age of study participants was 87.5 years, with a median follow-up duration of 24.0 months. The qualified success for a single SC-TCPC treatment at 1 and 2 years was 58.3% and 47.9%, respectively. Cumulative qualified success (>1 SC-TSCPC) was 64.6% at 1 year and 56.2% at 2 years. Complete surgical success after a single SC-TSCPC was 45.8% at 1 year and 33.3% at 2 years, increased to 50.0% at 1 year and 39.6% at 2 years after >1 SC-TSCPC. After SC-TSCPC treatment, the mean IOP decreased from 29.2±10.3 mmHg on 3.7±1.0 medications pre-treatment to 14.3±6.43 mmHg on 2.6±1.3 medications at the final follow-up visit (P<0.001). Seven eyes (14.6%) had SC-TSCPC retreatment, and two eyes (4.2%) required incisional glaucoma surgeries. Reported postoperative complications included: decreased visual acuity in 9 (18.8%) eyes, iridocyclitis in 5 (10.4%) eyes, hyphema in 5 (10.4%) eyes, cystoid macular edema in 2 (4.2%) eyes, and transient hypotony in 2 (4.2%) eyes.

Conclusions:
SC-TSCPC is an effective, relatively safe, and repeatable surgical treatment option in PXG. Further prospective investigations are suggested to confirm these findings.
Peer review comments: Friend or foe?
Authors: Hicks Rodney W. 
Published: January 2025

ABSTRACT
Peer review is a time-honored cornerstone of publishing. Peer reviewers, often blinded to the author, provide feedback to clarify the manuscript and validate the key messages and sciences. Authors may openly accept the feedback outright and make revisions. Authors may also view the feedback as intrusive and ill-mannered. Authors must revise the document promptly and consider each comment for merit. Tips for handling feedback are reviewed.
Metastasis-directed therapy in oligometastatic and oligoprogressive renal cell carcinoma
Authors: Dason Shawn , Wang Shang-Jui , Franceschelli Dominic , Singer Eric A. 
Published: January 2025

Purpose of review
This review addresses the evolving role of metastasis-directed therapy (MDT) in the management of oligometastatic and oligoprogressive renal cell carcinoma (RCC). With advances in both surgical techniques and stereotactic ablative radiotherapy (SABR), it is timely to explore how MDT can improve patient outcomes in these distinct disease states. The review highlights the potential of MDT to delay systemic therapy and improve quality of life while noting the lack of randomized clinical trial data guiding its use.

Recent findings
Recent literature emphasizes the outcomes of MDT, including metastasectomy and SABR, in managing oligometastatic and oligoprogressive RCC. Key studies suggest that MDT may prolong progression-free survival and delay systemic therapy. SABR has demonstrated high local control rates and manageable toxicity, offering a less invasive alternative to surgery. Despite these findings, there remains uncertainty about MDT's long-term impact on overall survival due to the absence of prospective randomized trials.

Summary
MDT holds promise in treating RCC by offering symptom relief, improving quality of life, and potentially delaying systemic therapy. However, the long-term benefits, particularly regarding survival outcomes, remain unclear. Further research, including prospective trials, is needed to better define the role of MDT in clinical practice, particularly in the absence of clear guidelines for patient selection.
Examining the Association Between Public Health Accreditation and COVID-19 Outcomes
Authors: Davis Mary V. , Rider Nikki , Rashied Ammar A. , Bhat Shankar , Lang Britt 
Published: January 2025

Objective:
To examine the association between local health department (LHD) accreditation and COVID-19 community outcomes, including rates of adult vaccination, hospitalization, and death.

Design:
We examined county level rates of adult vaccination, hospitalization, and death by LHD accreditation status over the course of the COVID pandemic. Additional independent variables included time period, COVID-19 Community Vulnerability Index (CCVI), state public health governance structure, and state policy environment. We used hierarchal linear mixed modeling with random intercept for county level data to account for repeated observations and fixed effects for all other variables.

Setting:
This study examined all communities in the United States of America.

Participants:
LHDs and the communities they serve.

Main Outcome Measures:
Rates of adult vaccination, hospitalization, and death due to COVID-19.

Results:
Among accredited LHDs, the adult population was more likely to be fully vaccinated when compared to unaccredited LHDs (P < .01). Additional variables in the model, which were also significant, included time period, CCVI, state policy environment, and state public health governance structure. There were no significant differences in the hospitalization rates in jurisdictions with an accredited LHD compared to jurisdictions where the LHD is not accredited. Death rates in jurisdictions with an accredited LHD were statistically significantly lower than death rates in jurisdictions where the health department was not accredited (P < .001). This relationship was significant with other key variables in the model, including time, CCVI, state policy environment, and state public health governance structure.

Conclusions:
This study demonstrates that there is an association between LHD accreditation and community health outcomes. Furthermore, we found that other factors, such as social determinants of health, state policy environment, and state public health governance structure impact community health outcomes.
Brief Report: Exploring PrEP Motivation as a Modifiable Target for HIV Prevention Uptake for Cisgender Women in Atlanta, Georgia
Authors: Anderson Katherine M. , Sheth Anandi N. , Sales Jessica M. 
Published: January 2025

Background:
Pre-exposure prophylaxis for HIV prevention (PrEP) prescriptions in the United States have increased, yet only 15% of individuals assigned female at birth who could benefit from PrEP had received prescriptions as of 2022, with marked racial disparities.

Setting:
Georgia has the highest HIV incidence of any United States state, with more than half of new cases occurring in Atlanta. Accounting for approximately 1-in-5 cases, cisgender women living in Atlanta may benefit from clinic-based efforts to increase PrEP uptake.

Methods:
We enrolled 102 women from PrEP-providing family planning clinics in the Atlanta metro area. After the clinic visit, women self-completed a questionnaire and a staff-administered questionnaire. Surveys were repeated at 3 and 6 months; using baseline data only, we conducted bivariate analyses to determine factors associated with willingness to use PrEP.

Results:
Participants were primarily Black (87.5%) and aged ≥24 (54.5%) years. Women considered their risk of next-year HIV diagnosis (70%) and HIV risk (85.8%) to be low, despite 45% endorsing perception of at least slightly risky sexual behavior. Most women (59.4%) were willing to take PrEP, although few were planning or had started to take PrEP. Lifetime gonorrhea or Trichomonas diagnosis, perceived sexual risk, perceived high/moderate HIV risk, and more positive PrEP attitudes scores were associated with PrEP willingness, as were individual PrEP attitudes, concerns/barriers, and stigma items.

Conclusions:
Findings suggest modifiable constructs that could be used by providers as interventional targets with patients to increase PrEP uptake. We provide suggestions mapped onto the Stages of Change Model and PrEP care and motivation continua.
Risk of adverse birth outcomes and birth defects among women living with HIV on antiretroviral therapy and HIV-negative women in Uganda, 2015–2021
Authors: Serunjogi Robert , Mumpe-Mwanja Daniel , Williamson Dhelia M. , Valencia Diana , Namale-Matovu Joyce , Kusolo Ronald , Moore Cynthia A. , Nyombi Natalia , Kayina Vincent , Nansubuga Faridah , Nampija Joanita , Nakibuuka Victoria , Nelson Lisa J , Dirlikov Emilio , Namukanja Phoebe , Mwambi Kenneth , Williams Jennifer L , Mai Cara T , Qi Yan Ping , Musoke Philippa 
Published: January 2025

Introduction:
We assessed the risk of adverse pregnancy and birth outcomes and birth defects among women living with HIV (WLHIV) on antiretroviral therapy (ART) and HIV-negative women.

Methods:
We analyzed data on live births, stillbirths, and spontaneous abortions during 2015–2021 from a hospital-based birth defects surveillance system in Kampala, Uganda. ART regimens were recorded from hospital records and maternal self-reports. Using a log-binomial regression model, we compared the prevalence of 16 major external birth defects and other adverse birth outcomes among WLHIV on ART and HIV-negative women.

Results:
A total of 203,092 births were included from 196,373 women of which 15,020 (7.6%) were WLHIV on ART. During pregnancy, 15,566 infants were primarily exposed to non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART (n=13,614; 87.5%). After adjusting for maternal age, parity, and number of antenatal care (ANC) visits, WLHIV on NNRTI were more likely than HIV-negative women to deliver preterm (adjusted prevalence ratio [aPR]=1.27, 95% confidence interval [CI]: 1.21,1.32), post-term (aPR=1.23, 95% CI: 1.16,1.32), or small for gestational age infants (aPR=1.35, 95% CI: 1.30,1.40). Spina bifida was more prevalent among infants born to WLHIV on ART periconceptionally compared to HIV-negative women (aPR=2.45, 95% CI 1.27,4.33). The prevalence of the other selected birth defects were similar between infants from WLHIV on ART and HIV-negative women.

Conclusion:
In Uganda, WLHIV on ART were more likely than HIV-negative women to experience selected adverse birth outcomes. Further surveillance of maternal ART exposure, including by drug class and ART regimen, is needed to monitor and prevent adverse birth outcomes in WLHIV.
A Novel Technique With Buttress Plating for Comminuted Base Fractures of the Proximal Phalanx
Authors: Cha Soo Min , Nho Jae Hwi , Ga In Ho , Kim Yong Hwan 
Published: January 2025

Background
Extra-articular but severely comminuted distal basal fractures of the proximal phalanx (PP) are rarely reported. Therefore, the aim of this study was to achieve proper union and desirable outcomes using low-profile locking plates/screws. We introduced our own surgical approach and reported the clinical/radiographic outcomes via retrospective case series.

Methods
Thirty-eight patients diagnosed with comminuted basal fracture of the PP were admitted between January 2014 and December 2020. Nineteen of these patients met the inclusion/exclusion criteria and were investigated in this retrospective study. Focusing only on preventing the volar tilt/collapse of the articular cartilage from the vertical position due to comminuted metaphysis, such as the “buttress concept by locking plate,” the defect was filled with bone grafts. Meticulous repair of the incised central tendon effectively stabilized it by tightening the sagittal band and capsule of the metacarpophalangeal joint. It also acted as an envelope with proper sealing to minimize the loss of grafted bone materials.

Results
Among the 19 patients, the mean patient age was 58.94 years, and the male/female ratio was 6:13. The mean follow-up period was 3.15 years, and the mean BMD was −0.15. Complete union was achieved after a mean of 9.63 weeks, without complications requiring secondary intervention. Two patients complained of skin lesion associated with PDS suture material, but this material spontaneously resolved by 4 weeks postoperatively. The mean extension lag at the proximal interphalangeal joint was 3.68 degrees, and the total active range of motion (TAM) was 256.38 degrees. Among the 19 patients, 6 were categorized as having a “good” modified Belsky classification, and the other patients all had an “excellent” classification. The mean articular-dorsal cortex angle was 85 ± 3.33 degrees at the final follow-up, which was slightly less than the normal value with statistical difference (P < 0.05); however, it did not correlate with the TAM statistically (r = 0.126, P = 0.608). Clinical outcomes were also satisfactorily evaluated using the VAS and DASH scores.

Conclusions
A low-profile locking plate is an effective option for extra-articular, severely comminuted basal fractures of the PP using the buttress concept in terms of clinical outcomes, such as finger movement and proper union.